Login to Your Account

FDA Stalls on Accelerated Nod, Seeks More Data on Eteplirsen

By Marie Powers
Staff Writer

Tuesday, April 16, 2013

Sarepta Therapeutics Inc. disclosed Monday afternoon following the market's close that the FDA has asked for additional information from its existing eteplirsen dataset before making a determination about a new drug application filing for the drug under Subpart H accelerated approval.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription